IMA vs RARE · rev $800.0K vs rev $350.0M
ImageneBio, Inc. (IMA) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
ImageneBio, Inc. (IMA) is a biotechnology company listed on NASDAQ.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported IMA revenue for 2025-09-30 was $800.0K. Net income was -$38.4M. Revenue was up 0.0% from 2025-06-30 to 2025-09-30. IMA currently screens at market cap $64.7M.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
IMA currently screens at market cap $64.7M. RARE currently screens at market cap $2.79B.
Not investment advice. Open the IMA and RARE stock pages for the full models.
Not investment advice.